|
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion
- ENJAYMO® (sutimlimab-jome) | What is ENJAYMO?
ENJAYMO is a chemotherapy-free treatment proven to help stop the destruction of red blood cells (hemolysis) in cold agglutinin disease (CAD)
- ENJAYMO® (sutimlimab-jome) | How ENJAYMO Can Help Treat CAD
ENJAYMO is a chemotherapy-free treatment option that helps stop hemolysis in its tracks What Happens in people living with CAD When you have Cold Agglutinin Disease (CAD), your immune system makes cold agglutinin antibodies that mistake red blood cells as a threat to the body When the antibodies come close to a red blood cell, they attach
- HIGHLIGHTS OF PRESCRIBING INFORMATION - enjaymo. com
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENJAYMO safely and effectively See full prescribing information for ENJAYMO ENJAYMO® (sutimlimab-jome) injection, for intravenous use Initial U S Approval: 2022
- ENJAYMO® (sutimlimab-jome) | ENJAYMO Dosing
The ENJAYMO dosing schedule is designed to provide a continuous level of medicine ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter
- ENJAYMO® (sutimlimab-jome) | What is Cold Agglutinin Disease?
ENJAYMO ® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) It is not known if ENJAYMO is safe and effective in children
- ENJAYMO® (sutimlimab-jome) | Resources
ENJAYMO resources and tools to help you get the information you need for people with cold agglutinin disease (CAD)
- Prescriber, please complete page 2 and have patient read and sign page 3.
information, with ENJAYMO the is medically information necessary on this form and any prescription to Recordati Rare Diseases, Inc (together with its parents and afiliates, “Recordati”) and its third-party business partners, I acknowledge vendors, that I and have other obtained agents authorization (“Agents”) to for release the
|
|
|